Oncogene-driven immune escape (OncoEscape)
Collaborative Research Centre 1479
The Collaborative Research Center (CRC) 1479 “Oncogene-driven immune escape” is a research consortium of clinical and basic tumor biologists and immunologist. Our CRC builds on the scientific hypothesis that oncogenic signalling and immune escape mechanisms are closely connected. This concept implies that targeting of oncogene-driven immune evasion could take treatment beyond palliative therapy towards cures for different types of cancer.
Seminars
News
Publications
Ozyerli-Goknar E PhD, Nizamuddin S, Fetsch V, Biniossek ML, Hartmann A, Perner F, McGeehan GM, Armstrong SA, Zeiser R, Timmers HTM. Menin-MLL inhibitors enhance JUND activity in MLLr leukemic cells contributing to tumorigenesis and therapy resistance. Blood. 2026 Jun 29:blood.2025032363. doi: 10.1182/blood.2025032363. Epub ahead of print.
Fleischhauer K, Toffalori C, Cugnata F, Hofmann JA, Orofino G, Lorentino F, Ahci-Hanci M, Lange V, Müller CR, Kunadt D, Bornhäuser M, Sanz G, Soiffer R, Waterhouse M, Giaccone L, Ali H, Nachtkamp K, Bacigalupo A, Bonifazi F, Luznik L, Facchini L, Bramanti S, Nagler A, Saccardi R, Milano F, Zallio F, Pierini A, Mohty M, Flomenberg N, Takaori-Kondo A, Vey N, Teshima T, Kröger N, Laperche CM, Andreani M, Lupo Stanghellini MT, Peccatori J, Di Serio C, Kobbe G, Al Malki MM, Bruno B, Zeiser R, Lindsley RC, Sanz J, Beelen D, Stölzel F, Sauter J, Schmidt AH, Ciceri F, Vago L; HLALOSS Consortium. Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol. 2026 Jun 25:JCO2600113. doi: 10.1200/JCO-26-00113. Epub ahead of print.
Rahbari M, Gris-Oliver A, Ramadori P, Aicher D, Sia D, Malek NP, Loomba R, Bataller R, Llovet JM, Heikenwälder M. The versatile interplay between steatotic liver disease and liver cancer. Nat Rev Cancer. 2026 Apr 14. doi: 10.1038/s41568-026-00918-y. Epub ahead of print.
More Publications
